YAP has also been reported to reprogram metabolism and DNA repair,36,37 drive lipid metabolic adaptation,38 and stabilize NRF2 signaling to promote redox balance and survival in HCC.39 These findings position dysadherin as a druggable upstream target to overcome YAP-mediated resistance. The gene discussed is FXYD5; the disease is hepatocellular carcinoma.